Castle Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Castle Biosciences
CSTL Stock  USD 29.56  0.01  0.03%   
Castle Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Castle Biosciences' valuation are provided below:
Gross Profit
273.2 M
Profit Margin
(0.07)
Market Capitalization
863.1 M
Enterprise Value Revenue
1.7793
Revenue
344.2 M
There are over one hundred nineteen available fundamental signals for Castle Biosciences, which can be analyzed over time and compared to other ratios. We recommend to validate Castle Biosciences' prevailing fundamental drivers against the all of the trends between 2010 and 2026.

Castle Biosciences Total Revenue

361.44 Million

Check Castle Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Castle Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 4 M, Net Interest Income of 14.9 M or Interest Income of 15.6 M, as well as many indicators such as Price To Sales Ratio of 3.11, Dividend Yield of 0.0 or PTB Ratio of 2.51. Castle financial statements analysis is a perfect complement when working with Castle Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Castle Stock
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.

Castle Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets374.5 M578.6 M206.3 M
Slightly volatile
Short and Long Term Debt Total23.2 M36.9 M19.4 M
Pretty Stable
Other Current Liabilities24.7 M48.2 M14.6 M
Slightly volatile
Total Current Liabilities72.1 M68.7 M22.6 M
Slightly volatile
Other Liabilities467.6 K492.2 K2.1 M
Very volatile
Property Plant And Equipment Net117.8 M112.2 M23.3 M
Slightly volatile
Current Deferred Revenue8 M7.6 M3.6 M
Slightly volatile
Accounts Payable19.6 M18.7 M4.5 M
Slightly volatile
Cash159.2 M116.7 M86.5 M
Slightly volatile
Non Current Assets Total228.3 M217.5 M63.6 M
Slightly volatile
Non Currrent Assets Other2.9 M5.6 M2.2 M
Slightly volatile
Other Assets2.4 M2.5 M2 M
Slightly volatile
Long Term Debt14.2 M8.8 M15.1 M
Slightly volatile
Cash And Short Term Investments236.9 M299.5 M128.5 M
Slightly volatile
Net Receivables26.6 M43.4 M16.3 M
Slightly volatile
Common Stock Total Equity30.2 K28.8 K12.8 K
Slightly volatile
Common Stock Shares Outstanding22.5 M29 M16.2 M
Slightly volatile
Long Term Debt Total22.5 M22.2 M19.2 M
Slightly volatile
Liabilities And Stockholders Equity374.5 M578.6 M206.3 M
Slightly volatile
Non Current Liabilities Total22.5 M39 M19.9 M
Pretty Stable
Capital Surpluse165.8 M157.9 M67.9 M
Slightly volatile
Inventory10.8 M10.3 M2.9 M
Slightly volatile
Other Current Assets5 M8 M2.9 M
Slightly volatile
Total Liabilities56.1 M107.7 M40.2 M
Slightly volatile
Property Plant And Equipment Gross91.2 M86.9 M21.5 M
Slightly volatile
Total Current Assets273 M361.1 M150.2 M
Slightly volatile
Net Working Capital229.2 M357.4 M133.1 M
Slightly volatile
Intangible Assets74.6 M109.9 M45.3 M
Slightly volatile
Common Stock22.3 K30 K12.8 K
Slightly volatile
Property Plant Equipment32 M30.5 M10.7 M
Slightly volatile
Capital Stock23.9 K25.2 K24.6 M
Slightly volatile

Castle Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income15.6 M14.9 M3.4 M
Slightly volatile
Depreciation And Amortization42.8 M40.8 M7.6 M
Slightly volatile
Interest Expense81.7 K86 K1.4 M
Slightly volatile
Selling General Administrative54.4 M88.1 M38 M
Slightly volatile
Total Revenue361.4 M344.2 M102.1 M
Slightly volatile
Gross Profit328.3 M312.6 M85.7 M
Slightly volatile
Other Operating Expenses406.4 M387 M122.7 M
Slightly volatile
Research Development32 M51.9 M19.1 M
Slightly volatile
Cost Of Revenue72.7 M69.2 M21 M
Slightly volatile
Total Operating Expenses406.4 M387 M110.1 M
Slightly volatile
Reconciled Depreciation19.3 M18.4 M4.9 M
Slightly volatile
Selling And Marketing Expenses118.7 M142 M95.5 M
Slightly volatile

Castle Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation26.3 M45.9 M14.3 M
Slightly volatile
Begin Period Cash Flow145.5 M119.7 M80.7 M
Slightly volatile
Depreciation42.8 M40.8 M7.6 M
Slightly volatile
Capital Expenditures37.8 M36 M7.9 M
Slightly volatile
End Period Cash Flow163 M137.7 M87.9 M
Slightly volatile
Issuance Of Capital Stock180.7 M288.1 M115.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.113.275610.879
Slightly volatile
Days Sales Outstanding43.745.999799.8804
Slightly volatile
Average Payables1 M1.2 M1.3 M
Slightly volatile
Stock Based Compensation To Revenue0.10.13330.0792
Slightly volatile
Capex To Depreciation0.840.88351.9078
Very volatile
EV To Sales2.893.043710.7438
Slightly volatile
Inventory Turnover8.7910.521111.4004
Slightly volatile
Days Of Inventory On Hand57.3434.692340.2712
Slightly volatile
Payables Turnover4.35.76584.9174
Slightly volatile
Sales General And Administrative To Revenue0.250.270.7234
Slightly volatile
Average Inventory661.2 K953.7 K783.1 K
Slightly volatile
Research And Ddevelopement To Revenue0.250.15060.2713
Slightly volatile
Capex To Revenue0.110.10460.0491
Slightly volatile
Cash Per Share7.710.33275.6044
Slightly volatile
Days Payables Outstanding80.1963.304877.4136
Slightly volatile
Intangibles To Total Assets0.130.17210.0972
Slightly volatile
Current Ratio6.515.25795.2182
Slightly volatile
Receivables Turnover3.987.93484.0826
Slightly volatile
Capex Per Share1.31.24270.3068
Slightly volatile
Average Receivables6.7 M7.5 M8.2 M
Slightly volatile
Revenue Per Share12.4711.87574.4848
Slightly volatile
Interest Debt Per Share1.451.27641.6342
Slightly volatile
Debt To Assets0.06060.06380.9842
Slightly volatile
Graham Number10.9114.0212.9358
Slightly volatile
Operating Cycle15480.692143
Slightly volatile
Days Of Payables Outstanding80.1963.304877.4136
Slightly volatile
Ebt Per Ebit0.980.68941.1743
Very volatile
Long Term Debt To Capitalization0.0660.06952.6114
Slightly volatile
Total Debt To Capitalization0.06910.07272.1523
Slightly volatile
Quick Ratio6.425.10865.1272
Slightly volatile
Net Income Per E B T1.030.81850.968
Slightly volatile
Cash Ratio1.611.69973.1221
Slightly volatile
Cash Conversion Cycle16.5217.387262.4833
Slightly volatile
Days Of Inventory Outstanding57.3434.692340.2712
Slightly volatile
Days Of Sales Outstanding43.745.999799.8804
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.420.44021.0526
Very volatile
Fixed Asset Turnover2.913.0678.9183
Slightly volatile
Debt Ratio0.06060.06380.9842
Slightly volatile
Price Sales Ratio3.113.275610.879
Slightly volatile
Asset Turnover0.640.5950.9207
Slightly volatile
Gross Profit Margin0.620.68660.7134
Slightly volatile

Castle Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap182.3 M205.1 M223.9 M
Slightly volatile
Enterprise Value198.4 M223.1 M243.6 M
Slightly volatile

Castle Fundamental Market Drivers

Castle Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Castle Biosciences Financial Statements

Castle Biosciences investors utilize fundamental indicators, such as revenue or net income, to predict how Castle Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue7.6 M8 M
Total Revenue344.2 M361.4 M
Cost Of Revenue69.2 M72.7 M
Stock Based Compensation To Revenue 0.13  0.10 
Sales General And Administrative To Revenue 0.27  0.25 
Research And Ddevelopement To Revenue 0.15  0.25 
Capex To Revenue 0.10  0.11 
Revenue Per Share 11.88  12.47 
Ebit Per Revenue(0.12)(0.13)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Castle Biosciences is a strong investment it is important to analyze Castle Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Castle Biosciences' future performance. For an informed investment choice regarding Castle Stock, refer to the following important reports:
How To Invest In Castle
Details
Is Castle Stock a good investment?
Details
What is Castle Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Castle Biosciences Correlation against competitors.
For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. Projected growth potential of Castle fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Castle Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.52)
Earnings Share
(0.44)
Revenue Per Share
11.876
Quarterly Revenue Growth
0.008
Return On Assets
(0.05)
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Castle Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Castle Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Castle Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY